More

    Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis



    [
    Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
    [og_img]
    https://www.investing.com/news/press-releases/immix-biopharma-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-nxc201-stericallyoptimized-cart-for-relapsedrefractory-al-amyloidosis-93CH-3859522


    Investing.com

    Latest articles

    spot_imgspot_img

    Related articles

    Leave a reply

    Please enter your comment!
    Please enter your name here

    spot_imgspot_img